Viatris Inc. (VTRS) Cash Flow Statement

The OCF/NI ratio is negative in most quarters, but this reflects large non-cash impairments and amortization rather than weak cash collection. For example, in 2025Q1, net income was -$3.0B while OCF was $535.5M, a gap of over $3.5B that is largely attributable to impairment charges. This suggests that the quality of earnings, when adjusted for non-cash items, is actually stable, though investors should monitor whether future impairments recur.

The FCF trajectory shows resilience, with 2025Q3 and 2025Q4 delivering $645.2M and $550.5M respectively, even as revenue growth has been negative. This suggests that the company's cash-generating ability is not directly tied to top-line growth, likely due to disciplined capex and working capital management. However, the most recent quarter's FCF margin of 8.8% is below the 10-quarter average, indicating some near-term pressure that warrants monitoring.

With CapEx/Rev consistently below 4% except for 2025Q4's 7.2%, Viatris appears to be running a lean capital expenditure program. This could be a deliberate strategy to maximize free cash flow for debt reduction, but it also raises questions about whether maintenance capex is sufficient to sustain the manufacturing footprint, especially given the recent FDA warning letter at the Indore facility. Investors should monitor whether future remediation costs force a step-up in capex.

The large negative working capital changes in 2025Q4 (-$1.4B) and 2026Q1 (-$702.9M) suggest aggressive paydown of payables or inventory build-up, which temporarily depressed operating cash flow. Conversely, positive changes in 2025Q3 and 2024Q4 boosted cash flow. This volatility implies that quarterly OCF figures are not a reliable run-rate indicator, and investors should focus on trailing twelve-month trends to assess underlying cash generation.

The company has consistently returned capital to shareholders, with dividends stable near $140M per quarter and buybacks occurring in several quarters, including $175M in 2025Q2. However, with FCF averaging around $445M per quarter, the payout ratio is roughly 60% when including buybacks, which may constrain the ability to deleverage further. Given the 'divest-to-delever' strategy, investors should assess whether this capital return is sustainable if FCF declines.

This massive gap between net income and operating cash flow is primarily driven by impairment charges, amortization, and other non-cash items, which are not reflective of the company's cash-generating ability. The persistence of this divergence suggests that GAAP earnings are not a useful metric for valuing Viatris, and investors should rely on cash flow-based valuation. However, the gap also highlights the risk that future impairments could further erode book value, even if cash flow remains stable.